Join the Oncology Voice Network. Join for Free
Why Companies Should Hire Aspiring MSLs (and How)
MSL role Medical Science Liaison aspiring MSLs networking in medical affairs diversity hiring in pharmaceuticals

Why Companies Should Hire Aspiring MSLs (and How)


Share This Article


Summary

In this episode, Alyson Evans joins Tom Caravela to discuss the evolving landscape of the MSL role. Alyson shares her career journey and offers insights on hiring practices, comparing the strengths of aspiring versus experienced MSLs. She provides comprehensive advice for those looking to break into the field, highlighting the importance of networking and purposeful diversity in hiring. Alyson also predicts future trends that could shape the MSL role. The episode wraps up with final thoughts and actionable advice for aspiring MSLs, encouraging listeners to remain proactive and engaged in their career development.

My guest today is Alyson Evans, Director, Medical Affairs with Sirtex Pharmaceuticals. Alyson discusses why companies should consider hiring aspiring MSLs.

She shares…

πŸ‘‰ Why she considers hiring aspiring MSLs and what her experience has been
πŸ‘‰ The advantages and disadvantages of hiring aspiring MSLs
πŸ‘‰ How to go about hiring aspiring MSLs
πŸ‘‰ What “purposeful diversity hiring” is
πŸ‘‰ What advice she has for aspiring MSLs looking to land a role as a Medical Science Liaison

Click for Source
MSL role, Medical Science Liaison, aspiring MSLs, networking in medical affairs, diversity hiring in pharmaceuticals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN